Skip to content

Schrodinger SDGR Additional Paid-In Capital

Additional Paid-In Capital at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$3.19B+25.0%
Absci Corporation logo
Absci CorporationABSI
$826.04M+12.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$196.62M+16.6%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$2.73B+7.6%
Certara, Inc. logo
Certara, Inc.CERT
$1.26B+2.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
$554.87M+2.8%

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.15B-23.7%
Enterprise value$984.71M-23.1%
P/S4.5×-2.0×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's additional paid-in capital?
Schrodinger (SDGR) reported additional paid-in capital of $1B in Q1 2026.
How has Schrodinger's additional paid-in capital changed year-over-year?
Schrodinger's additional paid-in capital increased by 4.6% year-over-year, from $958.03M to $1B.
What is the long-term trend for Schrodinger's additional paid-in capital?
Over 5 years (2020 to 2025), Schrodinger's additional paid-in capital has grown at a 5.7% compound annual growth rate (CAGR), from $752.56M to $992.02M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.